Transaction · 0001798679-26-000002

Matsuda Masaru

Matsuda Masaru, SR, reported an open-market or private sale at Arcutis Biotherapeutics, Inc. involving 884.000000 shares for an estimated $20871.77. Reported holdings after the transaction were 126689.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SSR
ARQTArcutis Biotherapeutics, Inc.
Trade date
May 04, 2026
Filing date
May 06, 2026
View on SEC Insider profile
Disclosed value-$20.8kShares × reported price
Shares traded884$23.61 per share
Holdings after126kDirect
% of reported position traded0.69%This security and ownership context
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 127,573 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

ARQT price since this filing

Daily closing prices, with the filing date and available return windows
ARQT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +3.2%1w ago +3.2%1d ago +0.0%
Returns since7d +0.0%30d -8.1%90d +11.5%180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001798679-26-000002
Common Stock
Transaction date
May 04, 2026
Filed May 06, 2026, 11:40 PM · 2d delay
Shares
884 sh
$23.61 per share
Estimated value
-$20.8k
Computed from shares × price
Holdings after
126,689 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

See Remarks

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on June 5, 2025, by the Reporting Person, with a plan end date of September 4, 2026.

  2. F2

    The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.1167 to $23.48, inclusive. The Reporting Person hereby underta…

  3. F3

    Due to a scrivener's error on the Reporting Person's Form 4 filed on March 3, 2026, the number of shares of common stock beneficially owned by the Reporting Person reflected a discrepancy that inadver…

  4. F4

    The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

  5. F5

    The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $23.16 to $23.93, inclusive. The Reporting Person hereby undertake…

Original filing · 0001798679-26-000002
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

ARQT